Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
W0027 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | W0027 |
| 2 | EXPERIMENTAL | W0027 |
| 3 | EXPERIMENTAL | W0027 |
| 4 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| W0027 | DRUG | capsule |
| Placebo | DRUG | Placebo |
Inclusion Criteria: * Subjects aged 18-65 years, who have been diagnosed with moccasin type tinea pedis (by positive dermatophyte culture, positive potassium hydroxide/calcofluor white preparation, and a Total Signs and Symptoms Score of at least 4). * Females of childbearing potential must use con...
W0027 is an investigational small molecule being developed for the treatment of tinea pedis, commonly known as athlete's foot. It is specifically being studied for moccasin type tinea pedis (MTTP), a form of the infection that affects the soles and sides of the feet.
W0027 is being developed by GSK plc, a global biopharmaceutical company listed on the stock exchange under the ticker symbol GSK. The company is conducting clinical research to evaluate the safety and efficacy of this investigational drug for the treatment of tinea pedis.
W0027 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to assess its safety and effectiveness. The drug is being studied for the treatment of tinea pedis.
W0027 has been studied in one completed clinical trial, identified as NCT00509275. This Phase 1 study evaluated the efficacy and safety of three W0027 regimens in the treatment of moccasin type tinea pedis. The trial enrolled 120 participants in the United States and Australia.
The specific molecular target of W0027 has not been disclosed. As a small molecule, it is designed to interact with biological pathways involved in the treatment of tinea pedis, a fungal infection of the skin. However, the exact mechanism of action has not been publicly detailed.
W0027 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The drug has completed one clinical trial, but it has not received regulatory approval for the treatment of tinea pedis or any other condition.